Nucleo

Name: Nucleo
Brand: Nucleo

AI Native

The online workplace for the life sciences industry connecting people, products and services.

Est 2024|Raised $500K

LinkedIn 4K|Web traffic 6K|FTEs 2|HQ San Francisco, California, US

Published Jul 14, 2026

01Common complaints

1. Organizations requiring proven, independently reviewed enterprise deployments immediately — limited independent review footprint and public case studies are available. 2. Organizations that require guaranteed, cleared regulatory status for production clinical decisions today — vendor materials indicate they are pursuing regulatory clearance; confirm current status before clinical reliance. 3. Organizations needing broad advanced visualization across many specialties — enterprise AV suites may provide a broader coverage set for multi-specialty needs. 4. Environments unable to accommodate new DICOM routing or cloud processing without clear hosting/integration documentation. 5. Budget-constrained organizations that require transparent pricing for ROI modeling prior to procurement.

Disqualifiers (poor fit)

Small clinics with low oncology imaging volume
Organizations that require documented security certifications (SOC 2 / ISO) publicly prior to pilot engagement, unless documentation can be provided under NDA
Sites that demand deep native integration into existing PACS/RIS with minimal IT effort, if the vendor requires manual upload workflows or custom integration work

Vendor-acknowledged limitations (public)

The vendor site does not present an explicit limitations section, public roadmap, or detailed failure-mode documentation.

Likely limitations (based on category; verify in pilot)

- Protocol sensitivity: CT acquisition differences (slice thickness, contrast timing) can affect measurements. - Edge cases: post-operative anatomy, metal artifacts, motion, and complex multi-lesion disease patterns may affect performance. - RECIST complexity: automation can assist measurement consistency but does not remove subjective elements such as target lesion selection and classification of new lesions. - Enterprise readiness questions: public documentation on security, auditability, and integration tooling is limited.

02Why they buy

Potential advantages (vendor-stated)

- Focus on oncology CT workflows including body composition metrics, lesion sizing, and target/non-target classification aligned to RECIST workflows. - Vendor-reported performance and speed metrics that, if validated in a specific deployment, could reduce staff time and improve measurement consistency. - Reported pilot engagements with well-known hospitals, which may indicate exposure to real-world imaging variability; buyers should verify the nature and scope of these engagements.

Areas where competitors may have advantages

Established advanced visualization vendors: deeper integration footprints, more documented regulatory history, and broader modality support.
Larger clinical AI vendors: more mature support organizations, formal SLAs, marketplace procurement pathways, and larger reference customer bases.

03Field reports

Review platform coverage (G2 / TrustRadius / Gartner Peer Insights)

No clearly attributable G2 product page or review corpus for Nucleo was located during searches.
TrustRadius did not surface a clearly attributable Nucleo product review page.
Gartner Peer Insights did not show an accessible review page for Nucleo.

Bottom line: there is no substantial third-party end-user review footprint readily available for Nucleo at the time of this research, which is common for very early-stage, hospital-pilot medtech.

Community / social discussion signals

The vendor name is ambiguous with other brands and products, so many community hits are unrelated. For Nucleo specifically: - The vendor maintains a social presence with modest follower counts; these are vendor-authored signals rather than independent reviews. - Company page content on professional networks reiterates speed/accuracy claims and hospital names; this material is vendor-authored rather than independent feedback. - No clear community discussion threads (e.g., community news and discussion sites) were identified for this product in targeted searches.

Direct quotes (vendor-reported and independent-evidence gap)

Independent review platforms and organic community threads for this product were not found; available quotable statements are vendor-reported metrics and accelerator page statements.

Vendor-reported claims include assertions such as a large acceleration in segmentation speed compared to manual methods and high agreement metrics with clinical experts. These claims have not been independently verified in public literature accessible during this research.

Why customers may choose the product (inferred from positioning)

Likely reasons a hospital or oncology group would evaluate Nucleo:

Reduce clinician time spent on manual segmentation and measurement
Improve measurement consistency across readers
Accelerate preparation for tumor boards and longitudinal comparison workflows

Why customers might discontinue use (common in this category; not Nucleo-specific)

Common reasons for churn in radiology AI and advanced visualization include:

Integration burden and workflow interruptions
Low clinician trust if false positives or measurement variance are high
Poor handling of edge cases such as artifacts or protocol variability
Procurement concerns if regulatory status or security posture is unclear

Public case studies

No detailed public case studies with named customers, deployment architecture, or ROI methodology were found on the vendor site during this research.

Vendor-published validation metrics (vendor-reported)

Vendor materials report performance claims such as substantial speed improvements compared with manual segmentation and strong agreement with clinical experts. These claims are provided by the vendor and lack accessible public study design details (e.g., sample size, external validation sets, scanner and protocol diversity, subgroup performance, and failure rates). Critical evaluation: for procurement and clinical validation, request the following from the vendor: - Full validation papers or technical whitepapers with methodology - Site-specific performance reports and reader study designs - Edge-case analyses (contrast phases, low-dose CT, motion, metal artifacts)

04Best fit

Organization size and types

Likely best fit:

Mid-to-large hospital systems and academic medical centers with high oncology CT volumes
Cancer centers with regular tumor boards and frequent longitudinal follow-up imaging
Clinical trials imaging cores that require standardized measurements, pending confirmation of trial governance features

Roles and personas

Decision makers: radiology leadership, oncology service line leadership, imaging informatics/PACS administrators, CIO/CTO, compliance/security teams, and clinical AI governance committees
Daily users: radiologists, oncologists, research coordinators, and imaging core lab staff

Pain points addressed

Labor burden associated with segmentation and measurement
Reader-to-reader variability in measurements
Time requirements for longitudinal tracking and reporting

05The pitch

What the product does (core value proposition)

Nucleo is an AI software product focused on automating CT scan analysis for oncology care. The product is described by the vendor as automating repetitive imaging tasks such as segmentation and measurement and extracting oncological imaging metrics to support tumor characterization and treatment decision processes. Primary vendor-stated use cases include: - Body composition and sarcopenia assessment (fat and muscle quantification on CT) - Tumor lesion sizing (consistent measurement) - Target vs. non-target lesion classification aligned with RECIST workflows (per vendor positioning) These descriptions are primarily vendor-published and emphasize reducing time spent on measurement and quantification steps rather than replacing radiologist interpretation end-to-end.

Target market and positioning

The vendor positions Nucleo as an AI-centered platform for oncology image analysis intended for: - Radiologists and oncologists working with CT imaging - Cancer centers and hospitals engaged in oncology imaging workflows - Potentially clinical trials imaging workflows (RECIST alignment suggests this), although explicit trial operations features are not clearly documented publicly Y Combinator materials state an objective of reducing time between imaging-derived metric production and downstream treatment decisions.

Get a comprehensive analysis of Nucleo including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →

Published Jul 14, 2026

01Common complaints

Organizations requiring proven, independently reviewed enterprise deployments immediately — limited independent review footprint and public case studies are available.
Organizations that require guaranteed, cleared regulatory status for production clinical decisions today — vendor materials indicate they are pursuing regulatory clearance; confirm current status before clinical reliance.
Organizations needing broad advanced visualization across many specialties — enterprise AV suites may provide a broader coverage set for multi-specialty needs.
Environments unable to accommodate new DICOM routing or cloud processing without clear hosting/integration documentation.
Budget-constrained organizations that require transparent pricing for ROI modeling prior to procurement.

Disqualifiers (poor fit)

Small clinics with low oncology imaging volume
Organizations that require documented security certifications (SOC 2 / ISO) publicly prior to pilot engagement, unless documentation can be provided under NDA
Sites that demand deep native integration into existing PACS/RIS with minimal IT effort, if the vendor requires manual upload workflows or custom integration work

Vendor-acknowledged limitations (public)

The vendor site does not present an explicit limitations section, public roadmap, or detailed failure-mode documentation.

Likely limitations (based on category; verify in pilot)

Protocol sensitivity: CT acquisition differences (slice thickness, contrast timing) can affect measurements.
Edge cases: post-operative anatomy, metal artifacts, motion, and complex multi-lesion disease patterns may affect performance.
RECIST complexity: automation can assist measurement consistency but does not remove subjective elements such as target lesion selection and classification of new lesions.
Enterprise readiness questions: public documentation on security, auditability, and integration tooling is limited.

02Why they buy

Potential advantages (vendor-stated)

Focus on oncology CT workflows including body composition metrics, lesion sizing, and target/non-target classification aligned to RECIST workflows.
Vendor-reported performance and speed metrics that, if validated in a specific deployment, could reduce staff time and improve measurement consistency.
Reported pilot engagements with well-known hospitals, which may indicate exposure to real-world imaging variability; buyers should verify the nature and scope of these engagements.

Areas where competitors may have advantages

Established advanced visualization vendors: deeper integration footprints, more documented regulatory history, and broader modality support.
Larger clinical AI vendors: more mature support organizations, formal SLAs, marketplace procurement pathways, and larger reference customer bases.

03Field reports

Review platform coverage (G2 / TrustRadius / Gartner Peer Insights)

No clearly attributable G2 product page or review corpus for Nucleo was located during searches.
TrustRadius did not surface a clearly attributable Nucleo product review page.
Gartner Peer Insights did not show an accessible review page for Nucleo.

Bottom line: there is no substantial third-party end-user review footprint readily available for Nucleo at the time of this research, which is common for very early-stage, hospital-pilot medtech.

Community / social discussion signals

The vendor name is ambiguous with other brands and products, so many community hits are unrelated. For Nucleo specifically:

The vendor maintains a social presence with modest follower counts; these are vendor-authored signals rather than independent reviews.
Company page content on professional networks reiterates speed/accuracy claims and hospital names; this material is vendor-authored rather than independent feedback.
No clear community discussion threads (e.g., community news and discussion sites) were identified for this product in targeted searches.

Direct quotes (vendor-reported and independent-evidence gap)

Independent review platforms and organic community threads for this product were not found; available quotable statements are vendor-reported metrics and accelerator page statements.

Why customers may choose the product (inferred from positioning)

Likely reasons a hospital or oncology group would evaluate Nucleo:

Reduce clinician time spent on manual segmentation and measurement
Improve measurement consistency across readers
Accelerate preparation for tumor boards and longitudinal comparison workflows

Why customers might discontinue use (common in this category; not Nucleo-specific)

Common reasons for churn in radiology AI and advanced visualization include:

Integration burden and workflow interruptions
Low clinician trust if false positives or measurement variance are high
Poor handling of edge cases such as artifacts or protocol variability
Procurement concerns if regulatory status or security posture is unclear

Public case studies

No detailed public case studies with named customers, deployment architecture, or ROI methodology were found on the vendor site during this research.

Vendor-published validation metrics (vendor-reported)

Critical evaluation: for procurement and clinical validation, request the following from the vendor:

Full validation papers or technical whitepapers with methodology
Site-specific performance reports and reader study designs
Edge-case analyses (contrast phases, low-dose CT, motion, metal artifacts)

04Best fit

Organization size and types

Likely best fit:

Mid-to-large hospital systems and academic medical centers with high oncology CT volumes
Cancer centers with regular tumor boards and frequent longitudinal follow-up imaging
Clinical trials imaging cores that require standardized measurements, pending confirmation of trial governance features

Roles and personas

Decision makers: radiology leadership, oncology service line leadership, imaging informatics/PACS administrators, CIO/CTO, compliance/security teams, and clinical AI governance committees
Daily users: radiologists, oncologists, research coordinators, and imaging core lab staff

Pain points addressed

Labor burden associated with segmentation and measurement
Reader-to-reader variability in measurements
Time requirements for longitudinal tracking and reporting

05The pitch

What the product does (core value proposition)

Body composition and sarcopenia assessment (fat and muscle quantification on CT)
Tumor lesion sizing (consistent measurement)
Target vs. non-target lesion classification aligned with RECIST workflows (per vendor positioning)

These descriptions are primarily vendor-published and emphasize reducing time spent on measurement and quantification steps rather than replacing radiologist interpretation end-to-end.

Target market and positioning

The vendor positions Nucleo as an AI-centered platform for oncology image analysis intended for:

Radiologists and oncologists working with CT imaging
Cancer centers and hospitals engaged in oncology imaging workflows
Potentially clinical trials imaging workflows (RECIST alignment suggests this), although explicit trial operations features are not clearly documented publicly

Y Combinator materials state an objective of reducing time between imaging-derived metric production and downstream treatment decisions.

Get a comprehensive analysis of Nucleo including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →